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Abstract 
Osteoinductive scaffolds are required for bone tissue engineering.  The aim of the present 
study was to assess the osteoinductive capacity of deoxyribonucleic acid (DNA)/protamine 
complexes in a rat model of critical-size calvarial defects.  In addition, we investigated 
whether cultured mesenchymal-like cells (DP-cells) outgrown from DNA/protamine complex 
engrafted defects could differentiate to become osteogenic cells in vitro.  DNA/protamine 
complexes were prepared by reactions between DNA and protamine sulfate solutions with 
stirring.  Critical-sized (8 mm) calvarial defects were created in the central parietal bones of 
adult rats.  Defects were either left empty or treated with DNA/protamine complex scaffolds. 
Subsequently, micro-computed tomography (micro-CT), histological, and 
immunohistochemical analyses were performed.  DP-cells were expanded from explants of 
DNA/protamine complex engrafted defects using an explant outgrowth culture system. 
Osteogenesis-related factors were assessed in DP-cells after treatment with an osteoblast-
inducing reagent (OIR).  After 3 months, nearly complete healing was observed for 
DNA/protamine complex engrafted calvarial defects.  Increased alkaline phosphatase (ALP) 
activity and Alizarin red staining were found for cultured DP-cells.  These cells had high 
expression levels of osteogenic genes, including those for RUNX-2, ALP, osteopontin, and 
osteocalcin.  These results indicated that DNA/protamine complexes could facilitate bone 
regeneration in calvarial defects.  Moreover, in vitro osteogenic induction experiments 
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showed that DP-cells outgrown from DNA/protamine engrafted defects had an osteogenic 
potential.  Based on these results, we suggest that DNA/protamine complexes may recruit 
osteocompetent cells in these defects, where they differentiate to osteogenic cells. 
Key words: DNA/protamine complex, scaffold, critical-size bone defect, bone regeneration, 
explant outgrowth culture 
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Introduction 
Satisfactory bone regeneration is necessary for healing critical-size bone defects (CSD) after 
skeletal injuries in orthopedic surgery, neurosurgery, and dentistry.  Traditional treatments for 
CSD involve supplemental bone grafting, which depends on the most common sources of 
harvested tissue, including bone auto- and allografts.  Among bones that are harvested, 
autogenous bone is regarded as the gold standard for bone graft materials because it provides 
the three elements necessary to generate and maintain the bone: scaffolding for 
osteoconduction; growth factors for osteoinduction; and progenitor cells for osteogenesis [1]. 
However, both auto- and allogenic bone harvests are limited in supply and associated with 
considerable donor site morbidities.  
Recent strategies for bone tissue engineering have focused on creating tissue 
engineered constructs that include cells to be transplanted embedded within supporting 
matrices and biomolecules [2, 3].  This approach incorporates an interactive triad of viable 
osteocompetent cells, soluble osteoinductive signals, and osteoconductive matrices or 
scaffolds, with the aim of favorable bone regeneration within the defects [3, 4].  
 Optimal scaffolds are required for both tissue engineered constructs and for host 
tissues around these defects.  For the engineered construct, the scaffolds must be able to 
deliver osteogenic cells and osteoinductive growth factors [5].  These scaffolds serve as a 
temporary matrix for cell migration, cell proliferation, and the deposition of extracellular 
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matrix components, with subsequent bone in-growth until a new bony tissue is totally 
regenerated [6].  In addition to biocompatibility, porosity, and surface properties, 
biodegradability and osteoinductivity are essential scaffold properties.  Biodegradable 
scaffolds obviate the need for a second surgical procedure.  These scaffolds should also be 
osteoinductive because they will stimulate osteocompetent cells that are recruited to a bone 
healing site and will undergo the osteogenic differentiation pathway [7].  
 We previously developed a biodegradable biomaterial comprising a mixture of salmon 
serum deoxyribonucleic acid (DNA) and protamine to be used as a scaffold for tissue 
engineering or drug delivery systems [8, 9].  The complex mixture prepared from DNA 
(mean of 300 base-pairs) and protamine could be turned into a paste by kneading in water [9, 
10].  This paste had suitable viscosity for clinical use. These DNA/protamine complexes also 
had favorable properties for biomaterials, such as a high affinity for calcium ions [10] and 
antibacterial activity [11].  The complex powder also showed no adverse effects for MC3T3-
E1 osteoblast-like cells, and had mild antibacterial activities and mild soft tissue responses 
[9].  
In addition, our group previously implanted these DNA/protamine complexes in 
calvarial defects created in rats and demonstrated that these complexes induced bone 
regeneration [12].  These results led us to hypothesize that these DNA/protamine complexes 
could stimulate osteocompetent cells, recruit them to a bone healing site, and undergo 
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osteogenic differentiation during the healing process. 
 Thus, the aim of the present study was to assess the osteoinductive capacity of our 
DNA/protamine complexes in a rat model of CSD.  In addition, we investigated whether 
cultured mesenchymal cells outgrown from DNA/protamine complex engrafted CSD could 
differentiate to become osteogenic cells in vitro.  
Materials and methods 
Preparation of DNA/protamine complex paste disks 
 DNA/protamine complex paste disks were prepared as previously described [12]. In 
brief, a solution of 300-bp fragments of sterilized salmon testis DNA was prepared and a 2% 
sterilized salmon testis protamine sulfate (MW = 4500) solution was provided by Maruha-
Nichiro Holdings, Ltd., Tokyo, Japan. Freeze–dried DNA/protamine complex powder was 
kneaded in distilled water to convert it into a paste. To prepare disks of this DNA/protamine 
complex paste, the DNA/protamine complex paste was injected into a silicone mold (internal 
diameter: 8 mm; height: 0.8 mm) on a Teflon plate.  The fabricated complex disks (40 mg) 
were immediately and carefully removed from the Teflon plate and silicone mold.  All 
procedures were performed under sterile conditions using sterilized instruments and 
materials. 
Rat model of critical-size calvarial bone defects 
 Disk implantation was performed as previously described [12].  In brief, 10-week-old 
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male Sprague–Dawley (SD) rats (weight approximately 300 g) were anesthetized with 2% 
isoflurane (Abbott Laboratories, Abbott Park, IL, USA) and an air mixture gas flow of 1.0 
L/min using an anesthesia gas machine (Anesthesia Machine SF-B01; MR Technology, Inc., 
Tsukuba, Ibaraki, Japan).  A critical-size calvarial bone defect CSD was created and treated 
with an 8-mm diameter paste disk for different observation times (1, 2, and 3 months) [12, 
13].   A control group included rats with CSD without these disks.  Three rats were used for 
each group for each time period. Our animal experimentation protocols were approved by the 
Animal Care and Use Committee of Fukuoka Dental College (No. 10017).  
Bone regeneration evaluations 
 Bone regeneration was evaluated using an in vivo micro-computed tomography 
(micro-CT) system (Skyscan-1176 micro-CT; Bruker, Kontich, Belgium) at 50 kVp and 500 
μA for rats while under anesthesia (as described above) at 1, 2, and 3 months after disk 
implantation.  Each image data set consisted of a scan size of approximately 35 μm.  The 
percentage of the newly formed bone in a calvarial bone defect (New-Bone%) was calculated 
as previously described [12].  
 After micro-CT scanning, rats were sacrificed by injecting an overdose of isoflurane. 
Following which, the cranial tissues that contained untreated or treated samples were 
immediately excised.  These samples were divided into three groups. For the first group of 
samples, tissue specimens were fixed in 4% paraformaldehyde in phosphate-buffered saline 
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(PBS), decalcified in 10% ethylenediamine tetraacetic acid (EDTA) for 4 weeks at 4°C, and 
then embedded in paraffin.  Paraffin sections (4 M) were then stained with hematoxylin and 
eosin (H&E) to visualize any histological changes.  
The second group of samples was immediately frozen in liquid nitrogen. Non-
decalcified frozen sections were processed for immunohistochemistry using primary rabbit 
anti-RUNX2 and mouse anti-osterix antibodies (1:100; Abcam) and goat anti-rabbit or mouse 
immunoglobulin G (IgG) conjugated with Alexa Fluor 488 or 568 (1:200; Molecular Probes, 
Eugene, OR, USA).  To visualize nuclei, immunostained cells were counterstained with 4,6-
diamidino-2-phenylindole (DAPI; Vector Laboratories Inc., Burlingame, CA, USA).  
The third group of samples (used as non-decalcified specimens) was stained with 
Villanueva osteochrome bone (VOB) stain.  For VOB staining, specimens were immersed in 
VOB solution for 3 days, dehydrated with a graded ethanol series, defatted in acetone, and 
then embedded in methyl methacrylate.  These specimens were sectioned at 20 m. The 
stained sections were observed for histology by fluorescence microscopy.  
Explant outgrowth culture of fibrous connective tissue from calvarial defects 
 Fibrous connective tissue (Fig. 1a) from the CSD at 2 weeks after DNA/protamine 
complex paste disk implantation and normal periosteum tissue (Fig. 1b) were used for an 
explant outgrowth culture system.  Primary cultures of mesenchymal cells (DP-cells) and 
periosteal cells (PO-cells) were obtained as outgrowths from the explants of connective tissue 
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from the CSD and periosteum tissue, respectively.  The tissues were cut into pieces of 
approximately 3 × 2 × 2 mm and placed on the bottoms of dishes.  They were allowed to 
adhere to these dishes and then cultured in Dulbecco’s modified Eagle’s medium (DMEM; 
Invitrogen, Tokyo, Japan) supplemented with 10% (v/v) fetal bovine serum (FBS; HyClone, 
Logan, UT, USA) and 1% (v/v) penicillin/streptomycin (PS; Invitrogen).  All cultures were 
maintained at 37°C in a humidified incubator and with 5% CO2.  After 21 days, outgrown 
cells from the explants were subcultured and maintained for up to an additional 7 days as 
secondary monolayers on tissue culture dishes before being used for assays.  
ALP assays 
 The effect of an osteoblast-inducer reagent (OIR) on alkaline phosphatase (ALP) in 
DP- and PO-cells was assessed by determining ALP activity and staining.  Both cell types 
were seeded at a density of 105 cells/well in 24-well microplates and exposed to DMEM with 
10% (v/v) and 1% (v/v) PS before incubation for 7 days at 37°C in an atmosphere of 5% 
CO2.  To induce the differentiation of both cell types, the medium was replaced every 2 days 
with DMEM with 10% (v/v) FBS that was supplemented with OIR (Takara Bio Inc., Otsu, 
Japan), which included ascorbic acid, hydrocortisone, and-glycerophosphate. The cells 
were cultured for 3, 7, 14, and 21 days.  
After incubation for the indicated time, the ALP activity was determined using a 
phosphatase substrate kit (AnaSpec, Inc., Fremont, CA), according to the manufacturer’s 
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instructions.  Optical densities were measured using a microplate reader at 405 nm. The 
results were obtained for triplicate samples and given as means ±standard deviations (SD’s). 
ALP expression was assessed in differentiated cells induced by OIR using an ALP staining kit 
(Takara Bio Inc., Otsu, Japan), according to the manufacturer’s instructions. 
Alizarin red staining  
 Both DP- and PO-cells were seeded at a density of 105 cells/well in 24-well 
microplates and exposed to DMEM with 10% (v/v) FBS and 1% (v/v) PS before incubation 
for 7 days at 37°C in an atmosphere of 5% CO2.  Osteogenic differentiation was induced by 
replacing the medium every 2 days with DMEM with 10% (v/v) FBS and OIR.  After 
differentiation for 14 days, the cells were washed twice with PBS, fixed for 10 min in 4% 
paraformaldehyde in PBS, and then rinsed twice with distilled water. These cells were stained 
at room temperature for 5 min with Alizarin red, excess dye was removed, and the cells were 
washed with distilled water.  Any calcified deposits that had stained red were photographed. 
Real-time reverse transcription-polymerase chain reaction (qRT-PCR) 
 Total ribonucleic acid (RNA) was isolated from tissues of DNA/protamine complex 
paste disk-implanted defects and normal periosteum, and DP- and PO-cells treated with OIR 
using an ISOGEN Kit (Roche Diagnostics, Tokyo, Japan), according to the manufacturer’s 
instructions.  Total RNA (1 g) was transcribed into cDNA using random and Oligo (dT) 
primers and reverse transcriptase in a total volume of 10 l (ReverTra® Ace qPCR RT Kit; 
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Toyobo Co., Ltd., Osaka, Japan).  Reverse transcription was performed at 37°C for 15 min 
and then at 98°C for 5 min.  The resulting templates were subjected to a LightCyclerNano 
real-time polymerase chain reaction (PCR) system according to the manufacturer’s protocol 
(Roche Diagnostics, Tokyo, Japan).  Glyceraldehyde-3-phosphate dehydrogenase (G3PDH) 
was used as an internal control.  Relative mRNA expression was determined as the ratio of 
RUNX-2, ALP, osteopontin (OPN), or osteocalcin (OCN) gene mRNA to G3PDH mRNA. 
All reactions were run in triplicate.  The primers used and TaqMan probes were as follows: 
G3PDH forward primer 5′-AATGTATCCGTTGTGGATCTGA-3′ and reverse primer 5′-
GCTTCACCACCTTCTTGATGT-3′, Universal ProbeLibrary probe no. 80; RUNX-2 forward 
primer 5′-GGCCCTGGTGTTTAAATGG-3′ and reverse primer, 5′- 
AGCACTCACTGACTCGGTTG-3′, Universal ProbeLibrary probe no. 83;  ALPforward 
primer 5′-ACGAGGTCACGTCCATCCT-3′ and reverse primer, 5′-
CCGAGTGGTGGTCACGAT-3′, Universal ProbeLibrary probe no. 89; OPN forward primer 
5′-GGCTACAGCATCTGAGTGTTTG-3′ and reverse primer, 5′-
CGGTGAAAGTGGCTGAGTTT-3′, Universal ProbeLibrary probe no. 82; OCN forward 
primer 5′-ATAGACTCCGGCGCTACCTC-3′ and reverse primer, 5′-
GCTTCACCACCTTCTTGATGT-3′, Universal ProbeLibrary probe no. 125.  
Immunocytochemistry 
 DP- and PO-cells were seeded on 13-mm cover glasses and cultured for 3, 7, 14, and 
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21 days. After culture for the indicated time, cells were fixed with 4 % paraformaldehyde for 
10 min and washed in 0.1% Triton X-100 in PBS for 15 min.  We simultaneously performed 
two types of double immunofluorescence staining for both cell types using two mixtures of 
two primary antibodies: (1) mouse monoclonal anti-rat prolyl-4-hydroxylase  (PHB, 1:100; 
Acris Antibodies GmbH, Herford, Germany) and rabbit polyclonal anti-RUNX-2 (1:100; 
Abcam, Tokyo, Japan); and (2) monoclonal anti-rat PHB (1:100; Acris Antibodies) and rabbit 
polyclonal anti-rat Sp7/osterix (1:100; Abcam), at 4°C overnight.  After washing with PBS, 
cells were incubated in a mixture of anti-mouse IgG antibody conjugated with Alexa Fluor 
488 (1:200; Molecular Probes, Eugene, OR, USA) and anti-rabbit IgG antibody (1:200; 
Molecular Probe) at room temperature for 30 min.  
Statistical analysis 
 The results are given as means ±SD’s. The group results were compared by one-way 
analysis of variance (ANOVA) and Scheffe’s multiple comparisons tests. A p value of <0.05 
was considered significant.  
Results 
DNA/protamine complexes heal critical-size rat calvarial defects  
To evaluate the potential for bone regeneration by our DNA/protamine complexes, CSD were 
created in the calvarial bones of 10-week-old SD rats.  These CSD cannot spontaneously heal 
during the bone healing period [14].  We first used micro-CT scanning and low-magnification 
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images of H&E stained sections to assess bone regeneration.  By 2 months postoperatively, 
micro-CT analyses showed that these defects had no evidence of new bone formation in the 
untreated rats, in agreement with the histological evidence (Fig. 2, upper and middle images 
at left).  In the DNA/protamine complex-implanted defects, micro-CT scans showed small 
peninsulas at 1 month.  Histologically, H&E-stained sections showed no residual materials 
within any of the defect regions and extensions of new bones from the edges of these defects 
(Fig. 2, upper images at right).  Both micro-CT and histological analyses showed an increase 
in peninsula extension at 2 months in the defects that had been implanted with 
DNA/protamine complexes (Fig. 2, middle images at right).  In the untreated defects at 3 
months, small peninsulas were observed by both micro-CT and histological analyses (Fig. 2, 
lower images at left). However, at 3 months, enhanced bony regeneration was observed in the 
defects that had been implanted with DNA/protamine complexes by both micro-CT and 
histological examinations (Fig.2, lower images at right).  
 We next quantified these micro-CT images for the percentage of defect healing by 
quantifying the pixels in these defects.  Percentage healing was determined by dividing the 
defect area by the defect size immediately postoperatively.  These results are summarized in 
Figure 3. Compared with the untreated rats (white bars), DNA/protamine complex-implanted 
rats (black bars) consistently showed higher percentages of new bone areas at each time 
point.  In the untreated rats, the empty defects had healed by less than 20% over the course of 
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3 months.  In contrast, the defects that were treated with DNA/protamine complexes showed 
>70% healing after 3 months.  These results demonstrated that these DNA/protamine 
complexes could promote bone regeneration in rat calvarial CSD.  
Histological bone healing processes in calvarial defects 
 We next investigated how these micro-CT findings reflected the histological bone 
healing processes in calvarial CSD at each time point using higher magnifications for the 
H&E-stained sections.  By 1 month after implantation, the defects had been replaced by a 
dense fibrous connective tissue that contained no material residues and a newly formed bone 
had extended from the edges of these defects (Fig. 4a).  Red immunofluorescence after VOB 
staining was observed in new bone extensions, which indicating that this newly formed bone 
was immature (Fig. 4d).  
Associated with the continuous extensions of a new bone from the edges of these 
defects, bone formation islands were observed in the fibrous connective tissue at 2 months 
after implantation (Fig. 4b).  VOB staining showed that both extension areas and new bone 
islands consisted of immature bone (Fig. 4e).  Greater bone formation was observed at 3 
months after implanting DNA/protamine complexes (Fig. 4c).  By VOB staining, most of the 
bone that had been replaced was in a mature condition, other than the peripheral areas of the 
bone (Fig. 4f).  These histological changes corresponded well with the micro-CT data.  
Tissue expression of osteogenic markers in calvarial defects implanted with 
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DNA/protamine 
 To determine if the cells included in the defects implanted with DNA/protamine 
complexes had osteoblastic properties, we immunostained non-decalcified frozen sections of 
these calvaria at 1 month after DNA/protamine complex implantation using an anti-RUNX-2 
antibody, a known osteoblast marker. RUNX-2 nuclear expression was observed in spindle-
shaped cells of fibrous connective tissue in these defects (Fig. 5a).  
We also examined the tissue expression of osteogenic genes’ mRNA by qRT-PCR. 
This indicated that the relative ALP and OCN mRNA expression levels (normalized to 
G3PDH mRNA expression) were increased by 33.3-fold and 5.4-fold, respectively, compared 
with that in normal periosteum (Fig. 5b).  Relative RUNX-2 and OPN mRNA expression was 
slightly increased as compared with that in normal periosteum.  These results indicated that 
the replacement tissue in those defects implanted with DNA/protamine complexes contained 
numerous cells with osteoblastic potential.  
Morphological characteristics of DP-cells after explant outgrowth culture  
 To determine the bone formation capacity of the cells that were replacing the calvarial 
defects, we developed an explant outgrowth culture system.  DP-cells were cultured as 
explants of the fibrous connective tissue in the defects that had been implanted with 
DNA/protamine complexes using DMEM supplemented with 10% FBS.  Cell growth by DP-
cells was similar to that of PO-cells. Cell migration and growth from the explants of the 
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fibrous connective tissue in defects occurred within 6–7 days, which was later than that 
observed for periosteal cultures (4–5 days), as shown in Figures 6a and b. Healthy, confluent 
cultures of DP-cells were obtained within 3 weeks as compared with 10–14 days for 
periosteal culture.  Although both cell types had spindle and/or polygonal shapes, cultured 
DP-cells (Fig. 6c) appeared to be slightly larger in size as compared with the cultured PO-
cells (Fig. 6d).  
Increased ALP activity and induction of calcified deposits in DP-cells treated with OIR 
 ALP activity is a well defined marker of osteogenesis and is assumed to reflect the 
degree of cell differentiation to osteoblasts [15].  We determined the ALP activity of DP- and 
PO-cells with and without OIR treatment for up to 21 days.  We first examined the ALP 
activity in DP- and PO-cells cultured without OIR. At 14 days, there were no significant 
differences in the ALP activity or ALP staining intensity between both cell types cultured 
without OIR (Fig. 7).  Figures 8a and b summarize the temporal changes in the ALP activity 
and ALP staining intensity for DP- and PO-cells cultured with OIR.  
On day 3, there was no significant difference in the ALP activity between DP- and 
PO-cells. The ALP activity and staining intensity of DP-cells increased from day 7 and 
peaked on day 14.  The ALP activity of these cells tended to decrease by day 21.  Compared 
with PO-cells, the ALP activity of DP-cells increased on days 7 and 14 by approximately 1.4-
fold and 11.2-fold, respectively, and was even approximately 8.1-fold higher on day 21. 
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These results indicated that DP-cells could differentiate to a progenitor condition for bone 
formation after OIR stimulation.   
 Alizarin red staining of cells was used to demonstrate a mineralized extracellular 
matrix as calcified deposits.  We examined if DP-cells cultured with OIR exhibited a late 
period of matrix maturation.  Almost all areas of the wells used for culture of DP-cells treated 
with OIR appeared red, whereas only tiny weak spots of Alizarin red staining were observed 
in wells used for culture of PO-cells (Fig. 8c).  These results indicated that the DP-cells 
treated with OIR had more calcification than the corresponding PO-cells.  
Increased osteogenic genes’ expression in DP-cells treated with OIR  
 To further investigate whether osteogenic genes could be induced in DP-cells treated 
with OIR, relative RUNX-2, ALP, OPN, and OCN mRNA expressions were analyzed by 
qRT-PCR. We first examined osteogenic genes’ mRNA expression in DP-cells cultured 
without OIR for 14 days. Compared with normal PO-cells, the relative OPN and OCN mRNA 
expression levels (normalized to G3PDH mRNA) were increased by 42.0-fold and 10.4-fold, 
respectively (Fig. 9).  RUNX-2 and ALP mRNA expression was only slightly increased.  
We also examined the temporal changes in the transcription levels of these marker 
genes in DP- and PO-cells treated with OIR, and compared these levels to those in PO-cells 
at day 0.  These results are summarized in Figure 10. Relative RUNX-2 and OCN mRNA 
expression in DP-cells treated with OIR gradually increased after day 7 and peaked on day 
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21. On day 21, the RUNX-2 and OCN mRNA levels were upregulated by 3.3-fold and 16.2-
fold, respectively, as compared with the levels in PO-cells. Relative ALP mRNA expression 
peaked on day 7 (4.2-fold higher). Relative OPN mRNA expression exhibited two peaks on 
days 0 (9.1-fold increase) and 14 (1.6-fold increase).  These results indicated that DP-cells 
had osteogenic properties regardless of the culture conditions used.  
RUNX-2 protein expression in DP-cells treated with OIR  
 We next examined protein expression for one of the osteogenic markers, RUNX-2, in 
DP- and PO-cells treated with OIR for 21 days by double immunocytochemistry analysis. 
Anti- proxyl-4-hydroxylase  was used as a marker of mesenchymal lineage for both cell 
types.  These results showed that RUNX-2 was expressed in the nuclei of DP-cells (Fig. 11a). 
In contrast, only faint or negative staining was found for PO-cells (Fig. 11b).  
Discussion 
It is believed that efficient regeneration of bone defects can be achieved by a combination of 
three regenerative elements: scaffolds, cells, and growth factors.  A number of scaffolds have 
been devised, including bioceramics, natural, and synthetic polymers, and applied clinically 
[16].  In the present study, we provided three lines of evidence that DNA/protamine 
complexes were osteoinductive factors for bone healing in rat calvarial CSD [12].  First, 
micro-CT and histological results confirmed that DNA/protamine complex engrafted defects 
had enhanced bone regeneration in our rat CSD model. Second, increased ALP activity and 
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induced calcified depositions were observed in OIR-cultured DP-cells that were outgrown 
from DNA/protamine complex engrafted defects.  Third, qRT-PCR and immunocytochemical 
data indicated that OIR-cultured DP-cells exhibited the characteristics of osteogenic cells.  
 Micro-CT analysis of DNA/protamine complex engrafted CSD indicated that these 
complexes could induce efficient bone regeneration.  Histological findings complemented 
these micro-CT results, in that they showed that the bone healing process consisted of new 
bone extensions from defect edges and islands of bone formation in connective tissue.  The 
new bone extension from bone defect edges is believed to be typical of bone healing, as 
shown by alveolar bones in a socket when a tooth is extracted.  The fibrous connective tissue 
of DNA/protamine complex engrafted defects contained a few islands of bones at 2 months 
after implantation.  
The appearance of discontinuous bones likely explains why these DNA/protamine 
complexes have the potential for ectopic bone formation.  These findings are supported by 
those in a previous report [12].  Moreover, immunohistochemical findings showed that the 
mesenchymal-like cells in defects expressed RUNX-2, indicating that there were numerous 
osteocompetent cells in DNA/protamine complex engrafted defects.  Thus, these results 
provide additional support for the osteogenic potential of DNA/protamine complexes in vivo.  
 Our results suggested that mesenchymal-like cells accumulated in DNA/protamine 
complex engrafted defects and appeared to have osteogenic potential. Thus, we developed an 
20 
 
explant outgrowth culture system to examine if these cells, DP-cells, in engrafted defects had 
osteogenic properties after treatment with OIR.  After expansion, these DP-cells were 
morphologically identical to PO-cells.  However, their response to OIR was completely 
different from that of PO-cells.  
The ALP activity of DP-cells peaked at 14 days after culture with OIR, which 
indicated that these cells had initiated osteoblastic differentiation because ALP levels are 
indicative of osteoblastic activity [15] and bone ALP is produced in extremely high amounts 
during the bone formation cycle [15].  After the peak in ALP activity, DP-cells exhibited a 
late period of osteoblastic differentiation, as shown by Alizarin red positive staining at 21 
days.  Because Alizarin red staining reflects a mineralized extracellular matrix produced by 
cells as calcified deposits, the maturation of DP-cells cultured with OIR proceeded with an 
increased ALP activity for 21 days.  These in vitro results likely support the bone 
regeneration process in DNA/protamine engrafted defects.  
 Our qRT-PCR and immunocytochemical results complemented the osteoblastic 
differentiation of DP-cells cultured with OIR.  We found that RUNX-2, ALP, OPN, and OCN 
gene expression was upregulated in DP-cells treated with OIR as compared with PO-cells. 
ALP and OPN mRNA expression levels were increased in DP-cells at days 7 and 14, 
respectively.  After these peaks of increased expression, both expressions were dramatically 
decreased.  The expression pattern of ALP mRNA was similar to that of the ALP activity, 
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even though increased ALP mRNA expression was earlier than that of the enhanced ALP 
activity.  
OPN is a non-collagenous, secreted glycosylation phosphoprotein that is expressed 
during the early stage of osteogenesis and is mass-produced when calcification begins [17]. 
The peak in OPN mRNA expression on day 14 appeared to reflect the initiation of 
calcification in DP-cells after treatment with OIR.  In contrast, increased RUNX-2 and OCN 
mRNA expression began and peaked at days 7 and 14, respectively.  
RUNX-2 is one of the transcription factors for BMP2 target genes and is essential for 
the development of the osteoblast phenotype. It is known that RUNX-2 is required for 
osteoblast differentiation and bone formation at the later stages of embryonic development 
[18, 19].  OCN is a specific non-collagen protein that is secreted by osteoblasts and is used as 
a marker for the late stage of osteoblast differentiation [15, 19].  Therefore, both these genes 
may participate in the late stage of osteoblast differentiation.  Our immunocytochemical 
analysis results complemented our qRT-PCR results by showing that RUNX-2 protein 
expression in DP-cells treated with OIR occurred at day 21 [20].  The higher expression 
levels of osteogenic genes and proteins by DP-cells cultured with OIR indicated that DP-cells 
had an enhanced capability to support osteogenic differentiation and/or maturation as 
compared with PO-cells.  
 In summary, we demonstrated that DNA/protamine complexes could facilitate bone 
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regeneration in rat calvarial defects.  Our in vitro experiments for osteogenic induction 
showed that DP-cells outgrown from DNA/protamine engrafted defects had an osteogenic 
potential.  Based on these results, we suggest that DNA/protamine complexes may recruit 
osteocompetent cells in these defects and differentiate to become osteogenic cells.  However, 
the detailed mechanisms for enhanced bone regeneration by DNA/protamine remain unclear. 
Future studies will address the detailed effects of DNA/protamine on microenvironments to 
induce osteogenesis in these bone defects. 
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Figure legends  
Figure 1 Tissue explants for outgrowth culture. (a) Fibrous connective tissue (rectangle) was 
replaced in a DNA/protamine paste-implanted calvarial defect. (b) Periosteum (rectangle) in 
rat calvarial bone.  The upper position of each picture is the skin side.  
Figure 2 Calvarial healing assessed by micro-computed tomography (micro-CT). Procedures 
for calvarial defects included no treatment (empty defects) and defects implanted with 
DNA/protamine complex paste disks. Micro-CT analysis and panoramic images of H&E 
staining up to 3 months (1 M, 2 M, and 3 M) revealed slight healing in empty defects. In 
contrast, DNA/protamine complexes nearly healed bone defects by 3 months.  
Figure 3 Quantitative results for micro-CT analysis.  Healing of defects is shown as the 
fraction of new bone with respect to the total defect area as quantified by micro-CT analysis 
(N = 5/group) *P < 0.05, compared with untreated defects.  
Figure 4 Representative H&E and VOB staining images during bone regeneration in rat 
calvarial defects.  (a)-(c) H&E staining of decalcified sections of defects after implanting 
DNA/protamine complexes at 1 (a), 2 (b), and 3 (c) months. (d)-(f) VOB staining for sections 
at 1 (d), 2 (e), and 3 (f) months. Bars = 500 m. 
Figure 5 Tissue expression of osteogenic markers in calvarial defects implanted with 
DNA/protamine complexes.  (a) Non-decalcified frozen sections at 1 month were stained 
with anti-RUNX-2.  (b) qRT-PCR analyses for RUNX-2, ALP, OPN, and OCN mRNA 
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expression (normalized to G3PDH mRNA) as compared with normal periosteum. Results are 
means ±SD's for 3-5 independent experiments.  
Figure 6 Growth initiation and morphological characteristics of connective tissue in 
bone defects and periosteal cultures.  Growth initiation from the explants of (a) connective 
tissue in defects (DP-cells) and (b) normal periosteum (PO-cells).  Confluent cultures of (c) 
DP-cells and (d) PO-cells. *, indicates explants. 
Figure 7 ALP activities and staining intensities of DP- and PO-cells cultured without 
OIR  (a) ALP activity of DP- and PO- cells cultured without OIR for 14 days. (b) ALP 
staining for DP- and PO- cells cultured without OIR for 14 days.  
Figure 8 ALP activity and mineralization of DP-cells treated with OIR.  (a) Total ALP 
activity of DP- and PO- cells treated with OIR for a period of 21 days. ALP activity levels 
were compared between DP- and PO-cells treated with OIR. Results are means ±SD's for 5 
independent experiments. *, significantly different at P < 0.05 compared with PO-cells. (b) 
ALP staining of DP- and PO-cells treated with OIR for a period of 21 days. Purple 
precipitates indicate ALP activity. (c) Cells from explants of DNA/protamine implanted tissue 
(DP-cells) or normal periosteal tissue (PO-cells) were incubated for 21 days without OIR 
(left) or with OIR (right). Matrix mineralization was visualized in OIR-cultured DP-cells by 
Alizarin red staining.  
Figure 9 Gene expression for osteogenesis markers in DP- and PO-cells without OIR 
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treatment for 14days.  qRT-PCR was used to determine RUNX-2, ALP, OPN, and OCN 
mRNA expression (normalized to G3PDH mRNA), as compared with normal periosteum. 
Results are means ±SD's for 3–5 independent experiments. 
Figure 10 Gene expression for osteogenesis markers in DP- and PO-cells treated with 
OIR.  qRT-PCR results for RUNX-2, ALP, OPN, and OCN mRNA expression in DP- cells 
(solid lines) and PO-cells (broken lines) treated with OIR.  Results are mRNA fold-increases 
(normalized to GAPDH mRNA) and compared with results for PO-cells treated with OIR on 
day 0. Vertical lines represent means ±SD's of 3 independent experiments, each performed in 
triplicate. *, significantly different at P < 0.05 compared with PO-cells.  
Figure 11 Immunocytochemical analysis of RUNX-2 protein expression in DP-cells 
treated with OIR for 21days.  Double immunofluorescence images using antibodies specific 
for proxyl-4-hydroxylase  (green) and RUNX-2 (red) for (a) DP-cells and (b) PO-cells.  
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